The VADEX technology platform is a self-adjuvanting protein nanoparticle platform. Its constituent units are formed by fusing a specific-sequence amphiphilic peptide with a superfolder green fluorescent protein. Although this amphiphilic peptide is only 19 amino acids long, it possesses both adjuvant functionality and nanoparticle self-assembly capability. Foreign proteins can be directly fused onto the nanoparticles or linked to the nanoparticles through irreversible complementary conjugation. Because nanoparticles formed using VADEX technology can induce long-lasting antibody responses without the need for external adjuvants, vaccines developed based on VADEX technology can withstand high temperatures of up to 40°C for more than two months. With this technology, children around the world, whether living in deserts or tropical rainforests, will be able to grow up healthy in the future.

1. EF-001 (Cerebraca® Wafer)
2. EF-009 Wafer
3. HK-001
4. EF-031
5. TSCA-001
6. EF-011

Apexcella Biomedical Inc. utilizes its proprietary ApexNK® cell culture platform, cryopreservation technology, and super-donor screening technology to develop autologous and allogeneic ApexNK® therapies, as well as a variety of CAR-NK immunotherapies. The company is committed to providing next-generation, innovative, low-side-effect, and widely applicable cell therapies for multiple types of cancer, striving to develop a diverse range of targeted cancer cell therapy solutions.

RephImmune is pioneering a new frontier in cancer immunotherapy with its proprietary platform, Reconstitute-Immunity Antigen-Cell Engager (RACE). This cutting-edge technology is rooted in regeneration biology and is specifically designed to reprogram and